Novo Nordisk advances obesity candidate to late stage program after weight loss of less than 12% Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Larvol Delta New semaglutide and cagrilintide semaglutide results possibilities in obesity and diabetes care